Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Sawai May Embark on Follow-on Antibody Drugs in Mid-2010s: President Sawai
July 11, 2011
- Application for Partial Changes Acceptable When Crystal Form Is Changed: Korosho
July 11, 2011
- Towa to Actively Develop Value Added Generics
July 11, 2011
- Korosho to Study Application of Cost-Benefit Assessment to Reimbursement Pricing
July 11, 2011
- Research-oriented Companies Provide Reliable Info. on Generics: Prof. Kobayashi
July 11, 2011
- PMDA to Bring Domestic GMP into Greater Harmony with PIC/S GMP
July 11, 2011
- Hospitals Lose Money by Using Herceptin for Stomach Cancer: Chuikyo's DPC Subcommittee
July 11, 2011
- Sanofi-aventis K.K. Aiming for Growth in “Upper Single Digits” Pres. Moulding
July 11, 2011
- Differences in Legal Positioning of Package Inserts between Japan, US, Europe Highlighted
July 11, 2011
- Rivastigmine “Highly Effective”in Early Treatment of AD: Prof. Nakamura
July 11, 2011
- Pfizer Aims to Boost Sales of Long-listed Drugs by Adding Indications, Dosage Forms
July 11, 2011
- MAA Accepted by EMA for Perampanel: Eisai
July 11, 2011
- Rivastigmine Is Recommended for Mild AD: Dr Endo of NCGG
July 11, 2011
- Nippon Kayaku: Pharm Sales Up 1.3% to ¥50,339 Mil.
July 11, 2011
- Protect NHI Prices of Essential Drugs: Mr Matsumori of Pfizer Japan
July 11, 2011
- More Participation in Homecare Essential to Increase Demand for Pharmacists: Report
July 11, 2011
- Maruishi Expects Growth in Domestic Sales in FY2011
July 11, 2011
- Applications Based on Data from Public Domain Recommended for 8 Drugs
July 11, 2011
- NST Reduces Hospitalization Cost by ¥0.4 Mil per Patient: NCGM
July 11, 2011
- KHK Preparing for Expected Leap in Growth from 2014-2015: President Matsuda
July 11, 2011
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…